We believe that GP96 is a potential target for the development of promising therapeutic strategies, including combination therapies as alternatives to conventional antibiotics and antiviral agents administered for broad-spectrum prevention, as well as management of secondary bacterial infections following influenza. This evidence concerns the gene HSP90B1 and bacterial infectious disease.